FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4327573670> ?p ?o ?g. }

• W4327573670 endingPage "218" @default.
• W4327573670 startingPage "218" @default.
• W4327573670 abstract "218 Background: Precision oncology trials in mCRPC rely on genomic profiling of tumor tissue but testing failure rates are 30-40%. Incorporating liquid biopsy screening into trial designs may address limitations of tissue-only genotyping. We report findings from the first 500 plasma samples screened on Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS), a phase II multicenter, eight-arm Canadian umbrella trial (NCT03385655) using circulating tumor DNA (ctDNA) to match mCRPC patients to biomarker (BM)-informed targeted therapies. Methods: mCRPC patients previously treated with novel androgen receptor inhibitor therapy were eligible after PSA and/or radiological progression. Plasma cell-free DNA and matched leukocyte DNA underwent deep targeted sequencing with an exon-limited panel (Feb 2017-Sep 2020), or an expanded panel integrating select introns and a genome-wide copy number grid (July 2020-present). A molecular tumor board (MTB) assigned patients to treatment arms based on prespecified BM criteria (BM+), or by randomization if BM negative (BM-). The primary endpoint was clinical benefit rate (PSA50 response; RECIST CR/PR; or SD ≥12 weeks). We report tumor content (ctDNA%), genomic alterations, and BM status for the whole cohort. Results: As of Nov 2021, 503 samples were screened from 444 patients, with 496 passing quality control. 345 samples (70%) had ctDNA ≥1% (ctDNA+), of which the median ctDNA fraction was 20% (IQR 6-44%). 72% of ctDNA+ samples were BM+ (52% of all screened samples). Driver alterations influencing BM status included AR (76%; 59% gain, 24% mutation), PI3K pathway (37%; PTEN 30%, PIK3CA 6%, AKT 3%), and DNA repair defects (26%: mismatch repair 5%, BRCA2 7%, ATM 6%, CDK12 7%, other 6%). The expanded panel detected additional intronic structural variants in baseline ctDNA+ samples ( PTEN 1% vs 25%; BRCA2 0.6% vs 5%; AR 16% vs 37%), and identified whole genome doubling and segmental deletion events. To date, 167 patients have been enrolled to a substudy (83 BM+, 84 BM-). Median time from blood draw to MTB decision improved over time (first vs second half of screening period: 28 vs 17d) with implementation of optimized lab workflows, standardized genomic reports, and hierarchical genomic eligibility assessment. As of Sep 2022, 485 patients have been screened (updated results will be presented). Conclusions: Prospective centralized screening of ctDNA is feasible for guiding precision oncology initiatives. Improvements to assay design, robust availability of targeted therapies and an adaptive approach to biomarker assessment allowed high detection of actionable tumor alterations. Our framework can be used in future trials to stratify patients according to genomic alteration status. Study accrual to PC-BETS is ongoing, with a screening target of 600 patients. Clinical trial information: NCT02905318, NCT03385655 ." @default.
• W4327573670 created "2023-03-17" @default.
• W4327573670 creator A5004331456 @default.
• W4327573670 creator A5005231494 @default.
• W4327573670 creator A5007564512 @default.
• W4327573670 creator A5020746955 @default.
• W4327573670 creator A5030667804 @default.
• W4327573670 creator A5034804495 @default.
• W4327573670 creator A5037530844 @default.
• W4327573670 creator A5042000897 @default.
• W4327573670 creator A5042123586 @default.
• W4327573670 creator A5044291041 @default.
• W4327573670 creator A5044585372 @default.
• W4327573670 creator A5045228937 @default.
• W4327573670 creator A5049918594 @default.
• W4327573670 creator A5053749991 @default.
• W4327573670 creator A5055207707 @default.
• W4327573670 creator A5060092380 @default.
• W4327573670 creator A5063121757 @default.
• W4327573670 creator A5064599843 @default.
• W4327573670 creator A5067610911 @default.
• W4327573670 creator A5089420153 @default.
• W4327573670 date "2023-02-20" @default.
• W4327573670 modified "2023-10-17" @default.
• W4327573670 title "Prospective ctDNA genotyping for treatment selection in metastatic castration-resistant prostate cancer (mCRPC): The Canadian Cancer Trials Group phase II PC-BETS umbrella study." @default.
• W4327573670 doi "https://doi.org/10.1200/jco.2023.41.6_suppl.218" @default.
• W4327573670 hasPublicationYear "2023" @default.
• W4327573670 type Work @default.
• W4327573670 citedByCount "1" @default.
• W4327573670 countsByYear W43275736702023 @default.
• W4327573670 crossrefType "journal-article" @default.
• W4327573670 hasAuthorship W4327573670A5004331456 @default.
• W4327573670 hasAuthorship W4327573670A5005231494 @default.
• W4327573670 hasAuthorship W4327573670A5007564512 @default.
• W4327573670 hasAuthorship W4327573670A5020746955 @default.
• W4327573670 hasAuthorship W4327573670A5030667804 @default.
• W4327573670 hasAuthorship W4327573670A5034804495 @default.
• W4327573670 hasAuthorship W4327573670A5037530844 @default.
• W4327573670 hasAuthorship W4327573670A5042000897 @default.
• W4327573670 hasAuthorship W4327573670A5042123586 @default.
• W4327573670 hasAuthorship W4327573670A5044291041 @default.
• W4327573670 hasAuthorship W4327573670A5044585372 @default.
• W4327573670 hasAuthorship W4327573670A5045228937 @default.
• W4327573670 hasAuthorship W4327573670A5049918594 @default.
• W4327573670 hasAuthorship W4327573670A5053749991 @default.
• W4327573670 hasAuthorship W4327573670A5055207707 @default.
• W4327573670 hasAuthorship W4327573670A5060092380 @default.
• W4327573670 hasAuthorship W4327573670A5063121757 @default.
• W4327573670 hasAuthorship W4327573670A5064599843 @default.
• W4327573670 hasAuthorship W4327573670A5067610911 @default.
• W4327573670 hasAuthorship W4327573670A5089420153 @default.
• W4327573670 hasConcept C121608353 @default.
• W4327573670 hasConcept C126322002 @default.
• W4327573670 hasConcept C143998085 @default.
• W4327573670 hasConcept C190283241 @default.
• W4327573670 hasConcept C203092338 @default.
• W4327573670 hasConcept C2777609662 @default.
• W4327573670 hasConcept C2780192828 @default.
• W4327573670 hasConcept C2781197716 @default.
• W4327573670 hasConcept C535046627 @default.
• W4327573670 hasConcept C55493867 @default.
• W4327573670 hasConcept C71924100 @default.
• W4327573670 hasConcept C86554907 @default.
• W4327573670 hasConcept C86803240 @default.
• W4327573670 hasConceptScore W4327573670C121608353 @default.
• W4327573670 hasConceptScore W4327573670C126322002 @default.
• W4327573670 hasConceptScore W4327573670C143998085 @default.
• W4327573670 hasConceptScore W4327573670C190283241 @default.
• W4327573670 hasConceptScore W4327573670C203092338 @default.
• W4327573670 hasConceptScore W4327573670C2777609662 @default.
• W4327573670 hasConceptScore W4327573670C2780192828 @default.
• W4327573670 hasConceptScore W4327573670C2781197716 @default.
• W4327573670 hasConceptScore W4327573670C535046627 @default.
• W4327573670 hasConceptScore W4327573670C55493867 @default.
• W4327573670 hasConceptScore W4327573670C71924100 @default.
• W4327573670 hasConceptScore W4327573670C86554907 @default.
• W4327573670 hasConceptScore W4327573670C86803240 @default.
• W4327573670 hasIssue "6_suppl" @default.
• W4327573670 hasLocation W43275736701 @default.
• W4327573670 hasOpenAccess W4327573670 @default.
• W4327573670 hasPrimaryLocation W43275736701 @default.
• W4327573670 hasRelatedWork W2004242127 @default.
• W4327573670 hasRelatedWork W2046855179 @default.
• W4327573670 hasRelatedWork W2231255144 @default.
• W4327573670 hasRelatedWork W2514214612 @default.
• W4327573670 hasRelatedWork W2783882412 @default.
• W4327573670 hasRelatedWork W2904621384 @default.
• W4327573670 hasRelatedWork W3154944633 @default.
• W4327573670 hasRelatedWork W3157765547 @default.
• W4327573670 hasRelatedWork W4225398559 @default.
• W4327573670 hasRelatedWork W16813516 @default.
• W4327573670 hasVolume "41" @default.
• W4327573670 isParatext "false" @default.
• W4327573670 isRetracted "false" @default.
• W4327573670 workType "article" @default.